BioLineRx Ltd. Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease

JERUSALEM--(BUSINESS WIRE)--BioLineRx (NASDAQ:BLRX) (TASE:BLRX) a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

Back to news